International Research Journal of Innovations in Engineering and Technology - IRJIET International Open Access, Monthly, Peer Reviewed, Reputed Journal ISSN (online): 2581-3048

Impact Factor (2025): 6.9

DOI Prefix: 10.47001/IRJIET

Corticosteroids versus Nanotechnology for SARS-CoV-2 Treatment

Abstract

Novel coronavirus or SARS-CoV-2 caused serious pandemic worldwide and led to significant mortality, morbidity and socioeconomic impact on population. To challenge this pandemic, several new approaches arose for diagnosis and treatment of COVID-19 infection. Drug repurposing is necessary action for this pandemic. According to World health organization approved that Corticosteroids are the effective drugs against viral infection and reduced mortality, but the major disadvantages are complications caused by these drugs, increased viral replication, and drug resistance. Because of its multivalent properties of Nanotechnology might become one of the possible and efficient treatment against viral infection and the major limitations are cost effective and requirement of clinical studies. This review summarizes the advantages, disadvantages, and limitations of corticosteroids from clinical studies, and then the applications of Nano medicine in diagnosis, therapy, and vaccine development for COVID-19 treatment. 

Country : India

1 Devendra Kumar Awasthi2 Silpa Rani Medapalli3 Abhinash Marukurti4 Vijaya Nirmala Pangi

  1. Department of Chemistry, Sri Jai Narain Mishra Post Graduate College, Lucknow, Uttar Pradesh, India
  2. Department of Chemistry, S.K.V.T College, Rajahmundry, Andhra Pradesh, India
  3. Department of Zoology, Adikavi Nannaya University, Rajahmundry, Andhra Pradesh, India
  4. Department of Zoology, Adikavi Nannaya University, Rajahmundry, Andhra Pradesh, India

IRJIET, Volume 5, Issue 12, December 2021 pp. 22-32

doi.org/10.47001/IRJIET/2021.512005

Full Paper
Download

References

  1. Rubio-Rivas, Manuel, et al. "Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness." International Journal of Infectious Diseases 101 (2020): 290-297.
  2. Ahmed, Mukhtar H., and Arez Hassan. "Dexamethasone for the treatment of coronavirus disease (COVID-19): a review." SN comprehensive clinical medicine (2020): 1-10.
  3. Tang, Xiao, et al. "Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial." Respiration 100.2 (2021): 116-126.
  4. Halpin, David MG, Dave Singh, and Ruth M. Hadfield. "Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective." European Respiratory Journal 55.5 (2020).
  5. Fadel, Raef, et al. "Early short-course corticosteroids in hospitalized patients with COVID-19." Clinical Infectious Diseases 71.16 (2020): 2114-2120.
  6. Castillo, Marta Entrenas, et al. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study." The Journal of steroid biochemistry and molecular biology 203 (2020): 105751.
  7. Veronese, Nicola, et al. "Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature." Frontiers in medicine 7 (2020): 170.
  8. Prescott, Hallie C., and Todd W. Rice. "Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic." Jama 324.13 (2020): 1292-1295.
  9. Sterne, Jonathan AC, et al. "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis." Jama 324.13 (2020): 1330-1341.
  10. Galvez‐Romero, Jose Luis, et al. "Cyclosporine A plus low‐dose steroid treatment in COVID‐19 improves clinical outcomes in patients with moderate to severe disease: a pilot study." Journal of internal medicine 289.6 (2021): 906-920.
  11. RECOVERY Collaborative Group. "Dexamethasone in hospitalized patients with Covid-19." New England Journal of Medicine 384.8 (2021): 693-704.
  12. Mikulska, Malgorzata, et al. "Tocilizumab and steroid treatment in patients with COVID-19 pneumonia." Plos one 15.8 (2020): e0237831.
  13. Van Paassen, Judith, et al. "Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes." Critical Care 24.1 (2020): 1-22.
  14. Farouq, Mohammed AH, et al. "Biomolecular interactions with nanoparticles: Applications for COVID-19." Current opinion in colloid & interface science (2021): 101461.
  15. Tavakol, Shima, et al. "The role of Nanotechnology in current COVID-19 outbreak." Heliyon (2021): e06841.
  16. Chauhan, Gaurav, et al. "Nanotechnology for COVID-19: therapeutics and vaccine research." ACS nano 14.7 (2020): 7760-7782.
  17. Nanotechnology versus coronavirus. (2020). Nature Nanotechnology, 15(8), 617–617. doi:10.1038/s41565-020-0757-7 
  18. Medhi, Riddhiman, et al. "Nanoparticle-based strategies to combat COVID-19." ACS Applied Nano Materials 3.9 (2020): 8557-8580.
  19. Idris, Adi, et al. "A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19." Molecular Therapy (2021).
  20. Rashidzadeh, Hamid, et al. "Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives." Nanomedicine 16.6 (2021): 497-516.
  21. Peters, Michael C., et al. "COVID-19–related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids." American journal of respiratory and critical care medicine 202.1 (2020): 83-90.
  22. Campos, Estefânia VR, et al. "How can nanotechnology help to combat COVID-19? Opportunities and urgent need." Journal of Nanobiotechnology 18.1 (2020): 1-23.
  23. Fouad, Ghadha Ibrahim. "A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19)." Bulletin of the National Research Centre 45.1 (2021): 1-22.
  24. Mainardes, Rubiana Mara, and CamilaDiedrich. "The potential role of nanomedicine on COVID-19 therapeutics." (2020): 411-414.
  25. Vahedifard, Farzan, and Krishnan Chakravarthy. "Nanomedicine for COVID-19: The role of nanotechnology in the treatment and diagnosis of COVID-19." Emergent materials (2021): 1-25.
  26. Kusumoputro, Sydney, et al. "Potential nanoparticle applications for prevention, diagnosis, and treatment of COVID‐19." View 1.4 (2020): 20200105.
  27. Yu, Zhongjie, et al. "Reactive oxygen species-related nanoparticle toxicity in the biomedical field." Nanoscale Research Letters 15 (2020): 1-14.
  28. Tabish, Tanveer A., and Michael R. Hamblin. "Multivalent nanomedicines to treat COVID-19: A slow train coming." Nano Today 35 (2020): 100962.
  29. Han Y, Král P: Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano 2020, 14:5143–5147.
  30. Z. Feng, B. Diao, R. Wang, G. Wang, C. Wang, Y. Tan, L. Liu, C. Wang, Y. Liu, Y. Liu, The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes, MedRxiv (2020).
  31. C. Liu, Q. Zhou, Y. Li, L.V. Garner, S.P. Watkins, L.J. Carter, J. Smoot, A.C. Gregg, A.D. Daniels, S. Jervey, Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases, ACS Publications, 2020.
  32. A.Łoczechin, K. S_eron, A. Barras, E. Giovanelli, S. Belouzard, Y.-T. Chen, N. Metzler-Nolte, R. Boukherroub, J. Dubuisson, S. Szunerits, Functional carbon quantum dots as medical countermeasures to human coronavirus, ACS Appl. Mater. Interfaces 11 (46) (2019) 42964–42974.
  33. I.D.L. Cavalcanti, SMdF. Ramos dos Santos Medeiros, DCdS. Macedo, I.M.F. Cavalcanti, MCdB. Lira Nogueira, Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: an alternative to COVID-19, Curr. Drug Deliv. (2020).
  34. Lima, T. L. C.; Feitosa, R. D. C.; Dos Santos-Silva, E.; Dos Santos-Silva, A. M.; Siqueira, E. M. D. S.; Machado, P. R. L.; Cornelio, ́ A. M.; Do Egito, E. S. T.; Fernandes-Pedrosa, M. D. F.; Farias, K. J. S.; Da Silva-Junior, A. A. Improving Encapsulation of Hydrophilic ́ ChloroquineDiphosphate into Biodegradable Nanoparticles: A Promising Approach against Herpes Virus Simplex-1 Infection. Pharmaceutics 2018, 10, 255.
  35. Yang, X. X.; Li, C. M.; Huang, C. Z. Curcumin Modified Silver Nanoparticles for Highly Efficient Inhibition of Respiratory Syncytial Virus Infection. Nanoscale 2016, 8, 3040−3048.
  36. Pardi N, Hogan MJ, Porter FW, Weissman D: mRNA vaccines  a new era in vaccinology. Nat Rev Drug Discov 2018, 17:261–279.
  37. McKay PF, Hu K, Blakney AK, Samnuan K, Brown JC, Penn R, et al.: Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun 2020, 11:3523.
  38. Mahase E: Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ 2020, 371:m4471.
  39. Huang, X.; Li, M.; Xu, Y.; Zhang, J.; Meng, X.; An, X.; Sun, L.; Guo, L.; Shan, X.; Ge, J.; Chen, J.; Luo, Y.; Wu, H.; Zhang, Y.; Jiang, Q.; Ning, X. Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus. ACS Appl. Mater. Interfaces 2019, 11, 19799−19807.
  40. Osminkina, L. A.; Timoshenko, V. Y.; Shilovsky, I. P.; Kornilaeva, G. V.; Shevchenko, S. N.; Gongalsky, M. B.; Tamarov, K. P.; Abramchuk, S. S.; Nikiforov, V. N.; Khaitov, M. R.; Karamov, E. V. Porous Silicon Nanoparticles as Scavengers of Hazardous Viruses. J. Nanopart. Res. 2014, 16, 2430.
  41. Lv, X.; Wang, P.; Bai, R.; Cong, Y.; Suo, S.; Ren, X.; Chen, C. Inhibitory Effect of Silver Nanomaterials on Transmissible VirusInduced Host Cell Infections. Biomaterials 2014, 35, 4195−4.
  42. WHO COVID-19 dash board 02-august-2021.

Copyright @ 2026-2017 IRJIET. All Right Reserved.

Developed by Byzero Technologies